Search
Aytu Biopharma Inc
AYTUAdd to Watchlist
2.160USD
+0.010+0.47%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
23.18MMarket Cap
LossP/E TTM
More Details of Aytu Biopharma Inc Company
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Aytu Biopharma Inc Info
Ticker SymbolAYTU
Company nameAytu Biopharma Inc
IPO dateOct 20, 2017
CEODisbrow (Joshua R)
Number of employees82
Security typeOrdinary Share
Fiscal year-endOct 20
Address7900 E. Union Avenue
CityDENVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80237
Phone17204376580
Websitehttps://aytubio.com/
Ticker SymbolAYTU
IPO dateOct 20, 2017
CEODisbrow (Joshua R)
Company Executives of Aytu Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. John A. Donofrio, Jr.
Mr. John A. Donofrio, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Abhinav (Abi) Jian
Mr. Abhinav (Abi) Jian
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Aytu Biopharma Inc?
The top five shareholders of Aytu Biopharma Inc are: Mr. Jarrett T. (Josh) Disbrow
How many institutions hold shares of Aytu Biopharma Inc (AYTU)?
As of 2026Q1, 69 institutions hold shares of Aytu Biopharma Inc, with a combined market value of approximately 3.87M, accounting for 36.10% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -493525.00.
What is the biggest source of revenue for Aytu Biopharma Inc?
In 2026Q1, the ADHD portfolio business generated the highest revenue for Aytu Biopharma Inc, amounting to 13.22M and accounting for 87.15% of total revenue.